Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Enterobacterales harbouring blaIMP-27 Genome sequencing and assembly

PROVIDER: PRJNA603518 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR11028800_1.fastq.gz	Fastqsanger.gz
	SRR11028800_2.fastq.gz	Fastqsanger.gz
	SRR11028801_1.fastq.gz	Fastqsanger.gz
	SRR11028801_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 59

Similar Datasets

Project description:Draft-whole genome sequencing of Enterobacterales possessing blaIMP-1 or blaIMP-6

| PRJNA980932 | ENA

Project description:Klebsiella pneumoniae co-harbouring blaNDM and blaIMP

| PRJNA942340 | ENA

Project description:ST131 harbouring CTX-M-27 in livestock UK

| PRJNA625187 | ENA

Enterobacterales

Project description:Enterobacterales Genome sequencing and assembly

| PRJNA640134 | ENA

Enterobacterales

Project description:Enterobacterales Genome sequencing and assembly

| PRJNA752009 | ENA

Enterobacterales

Project description:Enterobacterales Genome sequencing and assembly

| PRJNA1037737 | ENA

A multicenter translational biomarker phase II trial of regorafenib in patients with non-resectable pretreated colorectal cancer.

Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS). Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).

| 2533916 | ecrin-mdr-crc

Loss of histone demethylase JARID1C triggers genomic instability in cancer.

Project description:Chromatin remodelers are recurrently mutated in cancer. Among these, JARID1C, (KDM5C) a histone demethylase, is frequently inactivated in clear cell renal cell carcinoma (ccRCC) patients. How the genetic inactivation of JARID1C leads to cancer remains largely unknown. Here we report that JARID1C binds to broad chromatin domains characterized by the trimethylation of lysine 9 (H3K9me3), an histone mark enriched in heterochromatin. We also found that JARID1C localizes on heterochromatin, is required for heterochromatin replication, and forms a complex with established and novel players of heterochromatin assembly, such as SUV39H1 and HP1 and the CUL4 complex adaptor protein DDB1, respectively. To safeguard the genome, transcription on heterochromatin is tightly suppressed. JARID1C inactivation leads to the unrestrained expression of heterochromatic ncRNAs, that in turn trigger genomic instability. Remarkably, ccRCC patients harbouring JARID1C mutations show aberrant ncRNA expression and increased genomic rearrangements when compared with tumors endowed with other genetic lesions. Together, these data suggest that the inactivation of JARID1C in renal cancer leads to heterochromatin disruption and to aggressive, genomically rearranged ccRCCs, shedding light on a novel mechanism underlying genomic instability in sporadic cancers. We performed ChIP-sequencing for KDM5C, H3K9me3, H3K4me1 and H3K4me3 in Caki-1 untreated cells. Platform HiSeq2500.

2015-11-09 | E-GEOD-73267 | biostudies-arrayexpress

Project description:Full-length genome sequencing of Escherichia coli possessing blaIMP-1 or blaIMP-6

| PRJNA984319 | ENA

Project description:Enterobacterales isolates Genome sequencing and assembly

| PRJNA772899 | ENA